162 related articles for article (PubMed ID: 36978989)
1. Single-Cell Kinetic Modeling of β-Lapachone Metabolism in Head and Neck Squamous Cell Carcinoma.
Raddatz AD; Furdui CM; Bey EA; Kemp ML
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978989
[TBL] [Abstract][Full Text] [Related]
2. Genome-Scale Modeling of NADPH-Driven β-Lapachone Sensitization in Head and Neck Squamous Cell Carcinoma.
Lewis JE; Costantini F; Mims J; Chen X; Furdui CM; Boothman DA; Kemp ML
Antioxid Redox Signal; 2018 Oct; 29(10):937-952. PubMed ID: 28762750
[TBL] [Abstract][Full Text] [Related]
3. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
4. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
5. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
7. MTHFD2 Blockade Enhances the Efficacy of β-Lapachone Chemotherapy With Ionizing Radiation in Head and Neck Squamous Cell Cancer.
Shukla K; Singh N; Lewis JE; Tsang AW; Boothman DA; Kemp ML; Furdui CM
Front Oncol; 2020; 10():536377. PubMed ID: 33262939
[TBL] [Abstract][Full Text] [Related]
8. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
[TBL] [Abstract][Full Text] [Related]
10. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
11. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
12. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
14. β-lapachone regulates mammalian inositol pyrophosphate levels in an NQO1- and oxygen-dependent manner.
Eisenbeis VB; Qiu D; Gorka O; Strotmann L; Liu G; Prucker I; Su XB; Wilson MSC; Ritter K; Loenarz C; Groß O; Saiardi A; Jessen HJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2306868120. PubMed ID: 37579180
[TBL] [Abstract][Full Text] [Related]
15. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
16. Cancer Cell Sensitivity to Redox-Cycling Quinones is Influenced by NAD(P)H: Quinone Oxidoreductase 1 Polymorphism.
Glorieux C; Buc Calderon P
Antioxidants (Basel); 2019 Sep; 8(9):. PubMed ID: 31480790
[TBL] [Abstract][Full Text] [Related]
17. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation.
Zhao W; Jiang L; Fang T; Fang F; Liu Y; Zhao Y; You Y; Zhou H; Su X; Wang J; Liu S; Chen Y; Wan J; Huang X
Front Oncol; 2021; 11():747282. PubMed ID: 34676172
[TBL] [Abstract][Full Text] [Related]
18. β-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes.
Park JS; Lee YY; Kim J; Seo H; Kim HS
Free Radic Biol Med; 2016 Aug; 97():168-178. PubMed ID: 27242267
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
Pink JJ; Planchon SM; Tagliarino C; Varnes ME; Siegel D; Boothman DA
J Biol Chem; 2000 Feb; 275(8):5416-24. PubMed ID: 10681517
[TBL] [Abstract][Full Text] [Related]
20. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer.
Zhou L; Chen J; Sun Y; Chai K; Zhu Z; Wang C; Chen M; Han W; Hu X; Li R; Yao T; Li H; Dong C; Shi S
J Nanobiotechnology; 2021 Sep; 19(1):261. PubMed ID: 34481495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
